[go: up one dir, main page]

CL2017000819A1 - Métodos para separar diastereoisoméros de fosfato - Google Patents

Métodos para separar diastereoisoméros de fosfato

Info

Publication number
CL2017000819A1
CL2017000819A1 CL2017000819A CL2017000819A CL2017000819A1 CL 2017000819 A1 CL2017000819 A1 CL 2017000819A1 CL 2017000819 A CL2017000819 A CL 2017000819A CL 2017000819 A CL2017000819 A CL 2017000819A CL 2017000819 A1 CL2017000819 A1 CL 2017000819A1
Authority
CL
Chile
Prior art keywords
phosphate
methods
gemeitabine
alaninyl
diastereoisomers
Prior art date
Application number
CL2017000819A
Other languages
English (en)
Inventor
Hugh Griffith
Original Assignee
Nucana Biomed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nucana Biomed Ltd filed Critical Nucana Biomed Ltd
Publication of CL2017000819A1 publication Critical patent/CL2017000819A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

<p>ESTA SOLICITUD TIENE RELACIÓN CON UN MÉTODO PARA SEPARAR LOS DIASTEREOISÓMEROS DE FOSFATO DE GEMEITABINA-[ FENIL-BENZOXI-L-ALANINILO )]-FOSFATO ( NUC - 1031) USANDO CRISTALIZACIÓN. EN PARTICULAR, LA CRISTALIZACIÓN A PARTIR DE ISOPROPIL ALCOHOL PROPORCIONA GEMEITABINA-[FENILBENZOXI-L-ALANINILO)]-(S)-FOSFATO EN FORMA ALTA DISATEREOISOMÉRICAMENTE PURA. ESTA SOLICITUD TAMBIÉN TIENE RELACIÓN CON UNA FORMA CRISTALINA DE GEMEITABINA-[FENIL-BENZOXI-L-ALANINILO)]-(S)-FOSFATO.</p>
CL2017000819A 2014-10-06 2017-04-04 Métodos para separar diastereoisoméros de fosfato CL2017000819A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1417644.0A GB201417644D0 (en) 2014-10-06 2014-10-06 Method of separating phosphate diastereoisomers

Publications (1)

Publication Number Publication Date
CL2017000819A1 true CL2017000819A1 (es) 2017-11-03

Family

ID=51946917

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000819A CL2017000819A1 (es) 2014-10-06 2017-04-04 Métodos para separar diastereoisoméros de fosfato

Country Status (30)

Country Link
US (1) US10669300B2 (es)
EP (2) EP3204398B1 (es)
JP (2) JP6893172B2 (es)
KR (1) KR102532498B1 (es)
CN (2) CN107108682B (es)
AU (2) AU2015329767B2 (es)
CA (1) CA2959977C (es)
CL (1) CL2017000819A1 (es)
CY (1) CY1123061T1 (es)
DK (1) DK3204398T3 (es)
EA (1) EA033118B1 (es)
ES (1) ES2793957T3 (es)
GB (1) GB201417644D0 (es)
HR (1) HRP20200849T1 (es)
HU (1) HUE050882T2 (es)
IL (1) IL251125B (es)
LT (1) LT3204398T (es)
MA (1) MA41039B1 (es)
ME (1) ME03730B (es)
MX (2) MX373944B (es)
MY (1) MY183302A (es)
PH (1) PH12017500586A1 (es)
PL (1) PL3204398T3 (es)
PT (1) PT3204398T (es)
RS (1) RS60634B1 (es)
SG (2) SG10201902952SA (es)
SI (1) SI3204398T1 (es)
SM (1) SMT202000410T1 (es)
WO (1) WO2016055769A1 (es)
ZA (1) ZA201701723B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
CN104903339A (zh) 2012-11-16 2015-09-09 卡迪夫大学学院顾问有限公司 用于制备核苷前体药物的方法
PL3160978T3 (pl) 2014-06-25 2020-11-30 NuCana plc Proleki gemcytabiny
EA033046B1 (ru) 2014-06-25 2019-08-30 НУКАНА ПиЭлСи Состав, содержащий пролекарство гемцитабина
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药(苏州)股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药(苏州)股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN112156102B (zh) 2015-09-16 2023-10-03 济南高合医疗科技有限公司 一种nuc-1031单一异构体的晶型及其制备方法
WO2017060661A1 (en) 2015-10-05 2017-04-13 Nucana Biomed Limited Combination therapy
SG11201804774YA (en) 2015-12-11 2018-07-30 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522771D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
WO2018019188A1 (zh) * 2016-07-23 2018-02-01 博瑞生物医药(苏州)股份有限公司 核苷氨基磷酸酯类前药的多晶型及其制备方法
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CN107400156B (zh) * 2017-09-19 2020-01-31 北京大学 一种分离麦角甾烷型三萜25r-与25s-差向异构体的方法
CN115028594A (zh) * 2020-06-03 2022-09-09 吴卫东 恩替他滨药用前体化合物及其制备方法和医学用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058835A1 (en) * 2000-02-11 2001-08-16 Degussa Ag Resolution of dl-racemic mixtures
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
FR2954310B1 (fr) * 2009-12-18 2014-07-25 Univ Rouen Procede de dedoublement d'enantiomeres par evapocristallisation preferentielle
CN104903339A (zh) 2012-11-16 2015-09-09 卡迪夫大学学院顾问有限公司 用于制备核苷前体药物的方法
WO2014204856A1 (en) 2013-06-17 2014-12-24 Catabasis Pharmaceuticals, Inc. Fatty acid anticancer derivatives and their uses
WO2015081133A2 (en) * 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. Nucleotides for the treatment of liver cancer
PL3160978T3 (pl) 2014-06-25 2020-11-30 NuCana plc Proleki gemcytabiny
EA033046B1 (ru) * 2014-06-25 2019-08-30 НУКАНА ПиЭлСи Состав, содержащий пролекарство гемцитабина
JP6646663B2 (ja) 2014-07-22 2020-02-14 ニューカナ バイオメッド リミテッドNucana Biomed Limited ゲムシタビン−[フェニル(ベンゾキシ−l−アラニニル)]ホスフェートの製造方法リン酸誘導体を製造する方法
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
KR20180021697A (ko) 2015-05-14 2018-03-05 뉴카나 피엘씨 암 치료
WO2017060661A1 (en) 2015-10-05 2017-04-13 Nucana Biomed Limited Combination therapy
SG11201804774YA (en) 2015-12-11 2018-07-30 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
CA3008749C (en) 2015-12-23 2024-01-02 NuCana plc Treatment of ovarian cancer or biliary tract cancer with a combination of gemcitabine-(phenyl-benzoxy-l-alaninyl)]-phosphate and cisplatin
CA3008769A1 (en) 2015-12-23 2017-06-29 NuCana plc Combination therapy comprising nuc-1031 and cisplatin
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative

Also Published As

Publication number Publication date
JP6893172B2 (ja) 2021-06-23
AU2020203714A1 (en) 2020-06-25
GB201417644D0 (en) 2014-11-19
AU2015329767B2 (en) 2020-03-12
MX2017004446A (es) 2017-06-19
MX387346B (es) 2025-03-18
EP3725794A1 (en) 2020-10-21
JP2017530172A (ja) 2017-10-12
LT3204398T (lt) 2020-09-10
SMT202000410T1 (it) 2020-09-10
BR112017006855A2 (pt) 2017-12-12
KR102532498B1 (ko) 2023-05-12
PL3204398T3 (pl) 2020-11-16
SG11201701885UA (en) 2017-04-27
SI3204398T1 (sl) 2020-09-30
HUE050882T2 (hu) 2021-01-28
CN107108682A (zh) 2017-08-29
CY1123061T1 (el) 2021-10-29
KR20170090413A (ko) 2017-08-07
EA201790794A1 (ru) 2017-07-31
IL251125B (en) 2020-07-30
AU2015329767A1 (en) 2017-04-13
CN107108682B (zh) 2020-12-18
RS60634B1 (sr) 2020-09-30
EP3204398B1 (en) 2020-05-13
ZA201701723B (en) 2023-11-29
US20170226147A1 (en) 2017-08-10
MY183302A (en) 2021-02-18
CN112552362A (zh) 2021-03-26
PT3204398T (pt) 2020-05-28
WO2016055769A1 (en) 2016-04-14
EP3204398A1 (en) 2017-08-16
CA2959977A1 (en) 2016-04-14
MA41039B1 (fr) 2020-08-31
JP2020128392A (ja) 2020-08-27
ME03730B (me) 2021-01-20
JP6967625B2 (ja) 2021-11-17
ES2793957T3 (es) 2020-11-17
DK3204398T3 (da) 2020-06-02
MX2020003758A (es) 2021-10-26
PH12017500586A1 (en) 2017-08-30
SG10201902952SA (en) 2019-05-30
MX373944B (es) 2020-07-13
AU2020203714B2 (en) 2021-07-22
EA033118B1 (ru) 2019-08-30
CA2959977C (en) 2024-01-02
US10669300B2 (en) 2020-06-02
HRP20200849T1 (hr) 2020-10-30
IL251125A0 (en) 2017-04-30

Similar Documents

Publication Publication Date Title
CL2017000819A1 (es) Métodos para separar diastereoisoméros de fosfato
CL2018000096A1 (es) Anticuerpos específicos para tau hiperfosforilada y métodos de uso de los mismos.
CL2018000088A1 (es) Métodos para fabricar un compuesto elastómero reforzado con sílice y productos que lo contienen
EA202092987A2 (ru) Липид, содержащий докозапентаеновую кислоту
MX2016013963A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
CL2016000238A1 (es) Polimorfo de los inhibidores de la syk
CR20140534A (es) Proceso para la preparación de treprostinil y derivado de los mismos
CO2017012893A2 (es) Composiciones farmacéuticas que comprenden péptidos neo-antígenos o una sal de los mismos y métodos para preparar las mismas
MX338078B (es) Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos.
UY34108A (es) ?proceso para la fabricación de sustratos revestidos?.
MX2016013557A (es) Produccion de 4-metil-tetrahidropiranos 2-sustituidos a partir de materiales de partida con contenido de 2-alquil-4,4-dimetil-1,3-di oxanos.
EA201600429A1 (ru) Способ очистки 2,5-дихлорфенола
MX2018001793A (es) Compuestos para dispositivos opticamente activos.
EA201691006A1 (ru) Морфологические формы гексадецилоксипропиловых сложных эфиров фосфоновой кислоты и способы их синтеза
MX2016004565A (es) Preparacion de derivados de hidroxi - bencilbenceno.
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
CL2015002488A1 (es) Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen
EA201692288A1 (ru) Способ получения фосфорсодержащих циангидринов
AR101434A1 (es) Método para producir (r)-1,1,3-trimetil-4-aminoindano
MX2017000526A (es) Formulaciones de anticuerpos cristalinos.
CL2017001633A1 (es) Método de manufactura de proteína.
CR20140070A (es) Método para elaborar láminas a partir de pseudotallo de banano y láminas obtenidas usando dicho método
CL2016003351A1 (es) Lipido que comprende ácido docosapentanoico
EA201791329A1 (ru) Новые кристаллические формы мононатриевой соли форамсульфурона
CL2018001626A1 (es) Remoción de yeso de una solución de la lixiviación.